Carlsmed Reports Strong Q1 Revenue Growth, Improved Margins, and Positive CMS Reimbursement Developments
CARL is trading near its 52-week low of $8.5 (9.2% above the low).
Summary
Carlsmed reported strong Q1 2026 revenue growth and improved gross margins, driven by increased adoption of its spine surgery platform. Key product and regulatory milestones, including a positive CMS reimbursement proposal, underpin a positive outlook despite increased operating losses.
Key Events · Earnings and Guidance · CARL
-
Strong Revenue Growth
Revenue for the first quarter of 2026 increased by 58.2% year-over-year to $16.116 million, reflecting continued commercial adoption of the aprevo Technology Platform.
-
Improved Gross Margin
Gross margin improved to 77.1% in Q1 2026, up from 74.9% in Q1 2025, primarily due to cost improvements per unit from contract manufacturers.
-
Increased Net Loss and Cash Burn
Net loss for Q1 2026 increased to $(8.696) million from $(5.729) million in Q1 2025, and net cash used in operating activities rose to $(13.007) million, as the company continues to invest in product development and commercial expansion.
-
Positive CMS Reimbursement Developments
CMS released a proposal on April 10, 2026, for new MS-DRG coding that would reassign aprevo lumbar procedures to new codes, potentially providing additional reimbursement for hospital customers. NTAP for aprevo cervical inpatient procedures is effective October 1, 2025.
Analysis · CARL · Industrial Applications And Services
Carlsmed, Inc. reported robust first-quarter 2026 results, demonstrating significant commercial traction with a 58.2% year-over-year revenue increase and an improved gross margin. The company continues to expand its product portfolio with successful initial procedures for new cervical plating and bi-lateral lumbar solutions, signaling future growth opportunities. Critically, the recent CMS proposal for new MS-DRG codes for aprevo lumbar procedures, if finalized, represents a strong validation of the platform's value and could drive enhanced market adoption through additional reimbursement clarity. While net losses and cash burn increased due to continued investment in R&D and commercial expansion, the company maintains a solid liquidity position with over $97 million in cash and investments, projecting a runway of at least 12 months. The cashless exercise of warrants during the quarter also removes a potential overhang.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CARL was trading at $9.28 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $242.9M. The 52-week trading range was $8.50 to $17.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.